SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our analysis of the survival curves of transgenic p210BCR/ABL mice of different SOS1/2 genotypes revealed that starting the TAM induction of SOS1 ablation at 6 months of age, when the pathological hallmarks of CML are not yet manifested in the transgenic mouse strain used in these studies [33,34], resulted in a significant extension of lifespan and survival in comparison with the untreated control mice.